DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:14 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:14 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval
by Zacks Equity Research
FDA approval for DexCom's (DXCM) G6 Pro boosts the company's broad product spectrum.
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
IoMT Becomes the Buzzword in New Age MedTech Investing
by Urmimala Biswas
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.
DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
DexCom (DXCM) has various favorable factors to maintain the current high.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
by Zacks Equity Research
Solid growth in emerging markets is expected to be an added positive this earnings season.
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
by Zacks Equity Research
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Internet of Things Stocks to Buy for July
by Benjamin Rains
Today we've highlighted three, Zacks buy-ranked stocks with growing IoT businesses that investors might want to consider at the moment...
All You Need to Know About DexCom (DXCM) Rating Upgrade to Strong Buy
by Zacks Equity Research
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Profit from Surprise in Q2 2019 Earnings Season
by Benjamin Rains
Second quarter 2019 earnings season unofficially starts early next week when the big banks report. So let's take a look at some stocks that could shine for investors...
Will MedTech Ease Investors' Concern & Outperform? 4 Picks
by Urmimala Biswas
Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.
ETF & Stock Winners of Longest US Economic Expansion
by Sanghamitra Saha
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day
The Zacks Analyst Blog Highlights: JinkoSolar, Salem Media, Ciena, DexCom and Zumiez
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JinkoSolar, Salem Media, Ciena, DexCom and Zumiez
3 "Internet of Things" Stocks to Buy Right Now
by Benjamin Rains
Today we've highlighted three stocks with a Zacks Rank #2 (Buy) or better that could be poised for further IoT-based growth soon.
5 Top-Ranked Stocks Crushing the Market in June
by Sweta Killa
Wall Street has staged a nice comeback from the May swoon on hopes of monetary easing policies.
DexCom and Companion Medical Collaboration to Support CGM
by Zacks Equity Research
The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.
Here's Why You Should Invest in DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
Why Is DexCom (DXCM) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.